Skip to main content
×
Home
    • Aa
    • Aa

Parkinson's disease

  • William J Mutch (a1)
  • DOI: http://dx.doi.org/10.1017/S0959259800003944
  • Published online: 17 November 2008
Abstract
Copyright
Corresponding author
WJ Mutch, Associate Medical Director, The Dundee Healthcare Unit, Ashludie Hospital, Monifieth, Dundee DD5 4HQ, UK.
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1A Strudwick , WJ Mutch , I Dingwall-Fordyce . Parkinson's disease–functional impairment and who helps. Clin Rehabil 1990; 4: 213–16.

2Zhen-Xin Zhang , GC Roman . Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology 1993; 12: 195208.

3WJ Mutch , I Dingwall-Fordyce , AW Downie , JG Paterson , SK Roy . Parkinson's disease in a Scottish city. Br Med J 1986a; 292: 534–36.

4R D'Alessandro , G Gamberini , F Graniere , G Benassi , S Naccarato , D Manzaroli . Prevalence of Parkinson's disease in the Republic of San Marino. Neurology 1987; 37: 1679–82.

6NE Bharucha , EP Bharucha , AE Bharucha , AV Bhise , BS Schoenberg . Prevalence of Parkinson's disease in the Parsi Community in Bombay, India. Arch Neurol 1988; 45: 1321–23.

7AH Rajput , KP Offord , CM Beard , LT Kurland . Epidemiology of Parkinsonism: incidence, classification and mortality. Ann Neurol 1984; 16: 278–82.

8KP Ebmeier , SA Calder , JR Crawford , L Stewart , JAO Besson , WJ Mutch . Parkinson's disease in Aberdeen: survival after 3.5 years. Acta Neurol Scand 1990; 81: 294–99.

10GA Ricaurte , I Irwin , LS Forno , LE Delanney , EB Langston , JW Langston . Ageing and MPTP-induced degeneration of dopaminergic neurones in the substantia nigra. Brain Res 1987; 403: 4351.

11J De Pedro . Tracers for paralysis agitans in epidemiological research v. prevalence of the disease in Swedish counties. Neuroepidemiology 1986; 5: 207–19.

12BS Schoenberg . Clinical neuroepidemiology in developing countries. Neuroepidemiology 1982; 1: 137–42.

13WJ Mutch , WC Smith , RF Scott . A screening and alerting questionnaire for Parkinsonism. Neuroepidemiology 1991; 10: 150–56.

14RE Laporte . Assessing the human condition: capture-recapture techniques. Br Med J 1994; 308: 56.

16CD Ward , RC Duvoisin , SE Ince , JD Nutt , R Eldridge , DB Calne . Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology 1983; 33: 815–24.

17WG Johnson , Hodges, R Duvoisin . Twin studies and the genetics of Parkinson's disease-a reappraisal. Mov Disord 1990; 5: 187–94.

18LI Golbe , G Do Iorio , V Bonavita Autosomal dominant Parkinson's disease. Ann Neurol 1990; 27: 276–82.

19A Barbeau , M Roy . Familial subsets in idiopathic Parkinson's disease. Can J Neurol Sci 1984; 11: 144–50.

20PA Ballard , JW Tetrud , JW Langston . Permanent human Parkinsonism due to MPTP. Neurology 1985; 35: 949–56.

23SM Aquilonius , P Hartvig . A Swedish county with unexpectedly high utilisation of anti-Parkinsonian drugs. Acta Neurol Scand 1986; 74: 379–82.

24JW Langston , I Irwin . Pyridine toxins. In: DB Calne ed. Drugs for the treatment of Parkinson's disease. Handbook Exp Pharm 88. Berlin: Springer-Verlag, 1989: 205.

25KP Ebmeier , WJ Mutch , SA Calder , JR Crawford , L Stewart , JAO Besson . Does idiopathic Parkinsonism in Aberdeen follow intra-uterine influenza? J Neurol Neurosurg Psychiatry 1989; 52: 911–13.

26KM Semchuk , EJ Love , RG Lee . Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology 1992; 42: 1328–35.

27JP Hubble , BS Cao , RES Hassanein . JS Neuberger , WC Koller . Rick factors for Parkinson's disease. Neurology 1993; 43: 1693–97.

28PL McGeer , E McGeer , JS Suzuki . Ageing and extra-pyramidal function. Arch Neurol 1977; 34: 3335.

30WRG Gibb , AJ Lees . The progression of idiopathic Parkinson's disease is not explained by age-related changes. Clinical and pathological comparisons with post-encephalitic Parkinsonian syndrome. Acta Neuropathol 1987; 73: 195201.

31B Halliwell . Oxidants and the central nervous system: some fundamental questions. Acta Neurol Scand 1989; 80 (suppl 126): 2333.

32RR Ramsay , JI Salach , J Dadgar , TP Singer . Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic Parkinsonism. Biochem Biophys Res Commun 1986; 135: 269–75.

33VM Mann , JM Cooper , D Krige , SE Daniel , AHV Schapira , CD Marsden . Brain, skeletal muscle and platelet mitochondrial function in Parkinson's disease. Brain 1992; 115: 333–42.

34D Krige , MT Carroll , JM Cooper Platelet mitochondrial function in Parkinson's disease. Ann Neurol 1992; 32: 782–88.

35CAD Smith , AC Gough , PN Leigh Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992; 339: 1375–77.

36M Armstrong , AK Daly , S Cholerton , DN Bateman , JR Idle . Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 1992; 339: 1017–18.

37WD Parker , SJ Boyson , JK Parks . Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 1989; 26: 719–23.

39DT Dexter , FR Wells , AJ Lees Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 1989; 52: 1830–36.

40DT Dexter , C Carter , FR Wells Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989; 52: 381–89.

42CW Olanow . A scientific rationale for protective therapy in Parkinson's disease. J Neural Transm 1993; 91: 161–80.

44P Riederer , S Wuketich . Time course of nigrostriatal degeneration in Parkinson's disease. J Neural Transm 1976; 38: 227301.

45S Fahn , G Cohen . The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992; 32: 804–12.

46DB Calne . The free radical hypothesis in idiopathic Parkinsonism: evidence against it. Ann Neurol 1992; 32: 799803.

48WRG Gibb , AJ Lees . A comparison of clinical and pathological features of young-and old-onset Parkinson's disease. Neurology 1988; 38: 14021406.

50CJ Turnbull , JA Aitken . Diagnosis and management of ‘Parkinsonism’ in the elderly. Age Aging 1983; 12: 309–16.

51WJ Zetusky , J Jankovic , FJ Pirozzolo . The heterogeneity of Parkinson's disease: clinical and prognostic implications. Neurology 1985; 35: 522–26.

52M Hietanen , H Teravainen . The effect of age of disease onset on neuropsychological performance in Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 244–49.

54KP Ebmeier , SA Calder , JR Crawford , L Stewart , JAO Besson , WJ Mutch . Clinical features predicting dementia in idiopathic Parkinson's disease: a follow–up study. Neurology 1990; 40: 1222–24.

58S Gauthier , L Gauthier . Current status of levodopa therapy in idiopathic Parkinson's disease. Can J Neurol Sci 1987; 14: 452–54.

59SG Diamond , CH Markham , MM Hoehn , FH McDowell , MD Muenter . Effect of age at onset on progression and mortality in Parkinson's disease. Neurology 1989; 39: 1187–90.

60JA Wilson , RG Smith . The prevalence and aetiology of long-term L-dopa side-effects in elderly Parkinsonian patients. Age Ageing 1989; 18: 1116.

62CG Goetz , CM Tanner , GT Stebbins , AS Buchman . Risk factors for progression in Parkinson's disease. Neurology 1988; 38: 1841–44.

63JM Cederbaum . Clinical pharmacokinetics of anti-Parkinsonian drugs. Clin Pharmacokinet 1987; 13: 141–78.

64WH Poewe , AJ Lees , GM Stern . Treatment of motor fluctuations in Parkinson's disease with an oral sustained release preparation of L-dopa: clinical and pharmacokinetic observations. Clin Neuropharmacol 1986; 9: 430–39.

66R Pahwa , RN Busenbark , SJ Huber Clinical experience with controlled-release carbidopa/levodopa in Parkinson's disease. Neurology 1993; 43: 677–81.

68JG Nutt , WR Woodward , JH Carter , TL Trotman . Influence of fluctuations of plasma large neutral amino acids with normal diets on the clinical response to levodopa. J Neurol Neurosurg Psychiatry 1989; 52: 481–87.

69A Laihinen , JO Rinne , UK Rinne , M Haaparanta , U Ruotsalainen . F18-6-Fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (RO-462). Neurology 1992; 42: 199203.

70SA Factor , D Brown . Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov Disord 1992; 7: 125–31.

73UK Rinne . Dopamine agonist treatment in early Parkinson's disease. In: H Przuntek , P Riederer eds. Early diagnosis and preventive therapy in Parkinson's disease. Wien: Springer-Verlag, 1989: 343.

74AJ Lees , J Frankel , V Eatough , GM Stern . New approaches in the use of selegiline for the treatment of Parkinson's disease. Acta Neurol Scand 1989; 80 (suppl 126): 139–45.

77GL Zornberg . Severe adverse interaction between pethidine and selegiline. Lancet 1991; 337: 246.

78W Birkmayer , J Knoll , P Riederer , MBH Youdim , V Hars , J Marlon . Increased life expectancy resulting from addition of L-Deprenyl to Madopar treatment in Parkinson's disease: a long-term study. J Neural Transm 1985; 64: 113–27.

79JW Tetrud , WJ Langston . The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989; 245: 519–22.

80The Parkinson study group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989; 321: 1364–71.

81The Parkinson study group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993; 328: 176–83.

82Parkinson's Disease Research Group of the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Br Med J 1993; 307: 469–72.

83AJ Hughes , S Bishop , B Kleedorfer Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord 1993; 8: 165–70.

85WJ Weiner , SA Factor , JR Sanchez-Ramos Early combination (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology 1993; 43: 2127.

88O Lindvall , H Widner , P Rehncrona Transplantation of fetal dopaminergic neurons in Parkinson's disease: one year clinical and neuropsychological observations in two patients with putamenal implants. Ann Neurol 1992; 31: 155–65.

90CR Freed , RE Breeze , NL Rosenberg Survival of implanted fetal dopamine cells and neurological improvement 12 to 46 months after transplantation for Parkinson's disease. N Engl J Med 1992; 327: 1549–55.

91JS Schneider , A Pope , K Simpson , J Taggert , MC Smith , L de Stephano . Recovery from experimental Parkinsonism in primates with GMI ganglioside treatment. Science 1992; 256: 843–46.

92CG Goetz , MR Delong , RD Penn , RAE Bakay . Neurosurgical horizons in Parkinson's disease. Neurology 1993; 43: 17.

94LV Laitinen , AT Bergenheim , MI Hariz . Leksell's postero-ventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg 1992; 76: 5361.

95AL Benabid , P Pollak , C Gervason Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet 1991; 337: 403406.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Reviews in Clinical Gerontology
  • ISSN: 0959-2598
  • EISSN: 1469-9036
  • URL: /core/journals/reviews-in-clinical-gerontology
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×